Inflammation Blood Markers and Treatment Outcomes in Diffuse Large B-Cell Lymphoma
Studies whether blood inflammation markers predict response to R-CHOP chemotherapy in lymphoma patients.
Plain-language title generated from the registry record
Registry title: Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Key facts
- Where
- Cairo, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07057765, who can take part
Where in Egypt
- Clinical oncology and nuclear medicine Department, Faculty of medicine, Ain Shams UniversityCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07057765
- Record updated
- 10 July 2025
- Original description
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.Read full original descriptionShow less
Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Inclusion: Age ≥ 18 years and ≤ 65 years; Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL); Any stage of disease (nodal or extra-nodal), with or without B symptoms; Scheduled to receive standard systemic treatment (R-CHOP); ECOG performance status 0-2; Baseline normal:; Complete blood count (CBC); Hepatitis viral markers; Liver and renal function tests; Urine analysis; Echocardiogram; Additional investigations to exclude current infection if clinically indicated.
Exclusion: History of other concurrent or previous malignancies; Uncontrolled comorbid conditions that may interfere with study participation, including:; Diabetes mellitus; Autoimmune diseases; Active infections; Chronic inflammatory diseases; Cardiac dysfunction; Liver cell failure; Relapsed or refractory DLBCL; Pregnant females.